DOCSLIB.ORG

Comparison of Insulin Degludec/Insulin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparison of Insulin Degludec/Insulin 2084 Diabetes Care Volume 37, August 2014 Gregory R. Fulcher,1 Jens Sandahl Christiansen,2 Comparison of Insulin Ganapathi Bantwal,3 Miroslawa Polaszewska- Muszynska,4 Henriette Mersebach,5 Degludec/Insulin Aspart Thomas H. Andersen,5 and Leo K. Niskanen,6 on behalf of the BOOST: Intensify Premix I and Biphasic Insulin Aspart 30 Investigators in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial Diabetes Care 2014;37:2084–2090 | DOI: 10.2337/dc13-2908 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. This trial compared IDegAsp with biphasic insulin aspart 30 (BIAsp 30) in adults with type 2 diabetes inadequately controlled with once- or twice-daily (OD or BID) pre- or self-mixed insulin with or without oral antidiabetic drugs. RESEARCH DESIGN AND METHODS In this 26-week, randomized, open-label, multinational, treat-to-target trial, par- ticipants (mean age 58.7 years, duration of diabetes 13 years, BMI 29.3 kg/m2,and 1University of Sydney, Royal North Shore Hospi- HbA 8.4% [68 mmol/mol]) were exposed (1:1) to BID injections of IDegAsp (n = tal, Australia 1c 2Aarhus University Hospital, Aarhus, Denmark 224) or BIAsp 30 (n = 222), administered with breakfast and the main evening meal 3St. Johns Medical College Hospital, Bangalore, and dose titrated to a self-measured premeal plasma glucose (PG) target of 4.0– India 5.0 mmol/L. 4Bydgoszcz Diabetes and Endocrinology Center, Bydgoszcz, Poland 5 RESULTS Novo Nordisk A/S, Søborg, Denmark 6School of Medicine, University of Eastern Fin- After 26 weeks, mean HbA1c was 7.1% (54 mmol/mol) for both groups, with land, Helsingfors, Finland fi IDegAsp achieving the prespeci ed noninferiority margin for mean change in Corresponding author: Gregory R. Fulcher, greg. HbA1c (estimated treatment difference [ETD] –0.03% points [95% CI –0.18 to [email protected]. 0.13]). Treatment with IDegAsp was superior in lowering fasting PG (ETD –1.14 Received 16 December 2013 and accepted 20 mmol/L [95% CI –1.53 to –0.76], P < 0.001) and had a significantly lower final mean March 2014. daily insulin dose (estimated rate ratio 0.89 [95% CI 0.83–0.96], P = 0.002). Fewer Clinical trial reg. no. NCT01009580, clinicaltrials confirmed, nocturnal confirmed, and severe hypoglycemia episodes were reported .gov. for IDegAsp compared with BIAsp 30. This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/ CONCLUSIONS suppl/doi:10.2337/dc13-2908/-/DC1. IDegAsp BID effectively improves HbA and fasting PG levels with fewer hypo- © 2014 by the American Diabetes Association. 1c Readers may use this article as long as the work glycemia episodes versus BIAsp 30 in patients with uncontrolled type 2 diabetes is properly cited, the use is educational and not previously treated with once- or twice-daily pre- or self-mixed insulin. for profit, and the work is not altered. care.diabetesjournals.org Fulcher and Associates 2085 Insulin is the most effective therapy for in the subcutaneous tissue that slowly RESEARCH DESIGN AND METHODS achieving glycemic control in patients dissociate to provide continuous IDeg Trial Design with type 2 diabetes (1). Owing to the absorption to meet basal needs. At the A total of 50 sites in 10 countries (Aus- progressive nature of type 2 diabetes, same time, IAsp hexamers immediately tralia, Denmark, Finland, India, Malay- many patients will become candidates dissociate into monomers that are rap- sia, Poland, Sweden, Taiwan, Thailand, for prescription of insulindfrequently idly absorbed into the circulation, pro- and Turkey) participated in this multina- basal insulin initially on a variable back- viding mealtime coverage (13,14). tional 26-week, phase 3a, open-label, ground of antidiabetic therapy. How- Pharmacodynamic studies have demon- randomized, treat-to-target trial. ever, as type 2 diabetes progresses, strated that the glucose-lowering effect The protocol, protocol amendments, further treatment intensification in the of IDegAsp is characterized by a distinct consent form, and subject information form of prandial insulin is commonly peak action (from IAsp) and a separate sheet were reviewed and approved by required to achieve HbA1c targets and basal action (from IDeg). This is a closer health authorities according to local reg- potentially to avoid the long-term approximation of physiological ac- ulations and by the local independent consequences of hyperglycemia (2). tion than seen with current biphasic ethics committees prior to trial initia- Currently, this approach is achieved formulations. The long-acting basal tion. This trial was performed in accor- through the addition of one or more component of IDegAsp allows for a dance with the Declaration of Helsinki separate prandial insulin injections to pharmacodynamic profile that is flat and Good Clinical Practice (19). All study an existing basal insulin regimen or and stable throughout the day, mimick- participants gave written consent prior by switching to premixed insulin ing that of IDeg alone (14). The IDeg to any trial-related activities, and the in- containing a fixed ratio of rapid- and component in IDegAsp has been vestigator retained the consent forms. intermediate-acting insulin (1). However, demonstrated to have a predictable several barriers remain to insulin intensi- glucose-loweringeffectanduptofour Trial Population fication. While separate basal and bolus times lower day-to-day variability com- Adults with a clinical diagnosis of type 2 injections offer the most precise and pared with insulin glargine at steady- diabetes for $6 months were enrolled if adaptable mealtime glycemic control state conditions (15). Clinical trials they had an HbA1c of 7–10% (53–86 (1), they can be perceived as complex have demonstrated a lower risk of mmol/mol), had a BMI of #40 kg/m2, (1,3–5). In some patients, this may result IDeg causing hypoglycemia compared and were $18 years of age. Patients in an increased burden of treatments and with insulin glargine (16) and the possi- were on premixed human or analog decreased adherence to injections (6). bility of flexibility in the timing of injec- insulin or self-mixed insulin regimens Currently, available premix insulins tions (17). containing 20–40% fast-/rapid-acting offer a more convenient alternative, An earlier proof-of-concept study component, administered OD or BID with fewer injections and the potential demonstrated favorable efficacy and with or without OADs (metformin, sul- use of a single insulin pen device (7), safety profiles of IDegAsp as an add-on fonylureas, glinides, a-glucosidase but are associated with an increased to metformin in insulin-naive patients inhibitors, DPP-4 inhibitors, or pioglita- rate of postmeal hypoglycemia, including with type 2 diabetes inadequately con- zone) for $3 months prior to trial nocturnal hypoglycemia (8). The fear of trolled on oral antidiabetic drugs (OADs) initiation. hypoglycemia represents a significant (18). IDegAsp twice daily (BID) plus Patients were excluded if they had re- barrier to treatment (9,10). As a result, metformin provided overall glycemic ceived treatment in the 3 months prior patients with type 2 diabetes may con- control at lower insulin doses and signif- to trial initiation with other insulin regi- tinue to have poor glucose control and icantly lower rates of hypoglycemia mens, rosiglitazone, or a glucagon-like an increased risk of developing diabetes- compared with the widely used pre- peptide 1 receptor agonist or a history related complications (1). mixed insulin, biphasic IAsp 30 (BIAsp of recurrent severe hypoglycemia (more Comprising 70% insulin degludec 30) (NovoMix 30, NovoLog Mix 70/30; than one severe hypoglycemic episode (IDeg) and 30% insulin aspart (IAsp), Novo Nordisk A/S) in combination with during the past 12 months) or hypogly- IDegAsp (Ryzodeg; Novo Nordisk A/S, metformin in insulin-naive patients with cemic unawareness. Patients were also Bagsværd, Denmark) is the first soluble type 2 diabetes with an HbA1c of 7–11% excluded if they had cardiovascular dis- combination product of a basal insulin (18). These phase 2 results, while prom- ease (heart failure: New York Heart As- with an ultralong duration of action ising, were limited by a relatively small sociation class III or IV, unstable angina and a rapid-acting insulin in a single sample size (n = 61 in the IDegAsp arm; pectoris, or a myocardial infarction) injection. As a soluble coformulation, n = 60 in BIAsp 30 arm) and short study within 6 months preceding trial and un- IDegAsp does not require resuspension, duration (16 weeks). controlled severe hypertension (systolic which eases administration (11) and, In this phase 3a randomized, multi- blood pressure $180 mmHg or sitting more importantly, eliminates the risk national clinical trial, the efficacy and diastolic blood pressure $100 mmHg). of incomplete mixing and therefore in- safety of IDegAsp were compared with creased hypoglycemia (12). In solution, those of BIAsp 30 in adults with type Randomization the individual components of IDegAsp 2 diabetes inadequately controlled on After randomization, eligible patients exist separately as di-hexamers (IDeg) once-daily (OD) or twice-daily (BID) discontinued their diabetic treatment and hexamers (IAsp) (13). Upon injec- premixed or self-mixed insulin regi- except for metformin, DPP-4 inhibitors, tion, the IDeg di-hexamers assemble to mens with or without concomitant and pioglitazone and were switched form soluble and stable multihexamers OADs. from their prior insulin to IDegAsp or 2086 IDegAsp in Insulin-Treated Type 2 Diabetes Diabetes Care Volume 37, August 2014 BIAsp 30. Patients were randomized baseline in fasting PG (FPG) and the maintenance period after stable glyce- (1:1) to BID injections of IDegAsp (100 changes in nine-point self-measured mic control and insulin dose had been units/mL Ryzodeg) or BIAsp 30 (100 PG (SMPG) profiles.
Load more

Recommended publications
  • Rosiglitazone-Associated Fractures in Type 2 Diabetes an Analysis from a Diabetes Outcome Progression Trial (ADOPT)
    Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Rosiglitazone-Associated Fractures in Type 2 Diabetes An analysis from A Diabetes Outcome Progression Trial (ADOPT) 1 7 STEVEN E. KAHN, MB, CHB DAHONG YU, PHD preclinical data and better understand the 2 7 BERNARD ZINMAN, MD MARK A. HEISE, PHD clinical implications of and possible interven- 3 7 JOHN M. LACHIN, SCD R. PAUL AFTRING, MD, PHD tions for these findings. 4 8 STEVEN M. HAFFNER, MD GIANCARLO VIBERTI, MD 5 WILLIAM H. HERMAN, MD FOR THE ADIABETES OUTCOME Diabetes Care 31:845–851, 2008 6 RURY R. HOLMAN, MD PROGRESSION TRIAL (ADOPT) STUDY 7 BARBARA G. KRAVITZ, MS GROUP* ype 2 diabetes is associated with an increased risk of fractures, with the risk increasing with longer duration OBJECTIVE — The purpose of this study was to examine possible factors associated with the T increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial of disease (1,2). These fractures affect pre- (ADOPT). dominantly the hip, arm, and foot (1–5) and occur despite the fact that bone min- RESEARCH DESIGN AND METHODS — Data from the 1,840 women and 2,511 men eral density is either normal or even in- randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years creased in patients with type 2 diabetes were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. compared with those who are not hyper- glycemic (5–7). Although the reason for RESULTS — In men, fracture rates did not differ between treatment groups.
    [Show full text]
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • The Antidiabetic Drug Lobeglitazone Has the Potential to Inhibit PTP1B T Activity ⁎ Ruth F
    Bioorganic Chemistry 100 (2020) 103927 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B T activity ⁎ Ruth F. Rochaa, Tiago Rodriguesc, Angela C.O. Menegattia,b, , Gonçalo J.L. Bernardesc,d, Hernán Terenzia a Centro de Biologia Molecular Estrutural, Departamento de Bioquímica, Universidade Federal de Santa Catarina, Campus Trindade, 88040-900 Florianópolis, SC, Brazil b Universidade Federal do Piauí, CPCE, 64900-000 Bom Jesus, PI, Brazil c Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal d Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK ARTICLE INFO ABSTRACT Keywords: Protein tyrosine phosphatase 1B (PTP1B) is considered a potential therapeutic target for the treatment of type 2 Thiazolidinediones diabetes mellitus (T2DM), since this enzyme plays a significant role to down-regulate insulin and leptin sig- Lobeglitazone nalling and its over expression has been implicated in the development of insulin resistance, T2DM and obesity. PPAR-γ Some thiazolidinediones (TZD) derivatives have been reported as promising PTP1B inhibitors with anti hy- PTP1B perglycemic effects. Recently, lobeglitazone, a new TZD, was described as an antidiabetic drug that targetsthe Non-competitive inhibitors PPAR-γ (peroxisome γ proliferator-activated receptor) pathway, but no information on its effects on PTP1B have been reported to date. We investigated the effects of lobeglitazone on PTP1B activity in vitro. Surprisingly, lobeglitazone led to moderate inhibition on PTP1B (IC50 42.8 ± 3.8 µM) activity and to a non-competitive reversible mechanism of action.
    [Show full text]
  • Effect of Glucose/Sulfonylurea Interaction on Release of Insulin
    Proc. Nati. Acad. Sci. USA Vol. 76, No. 11, pp. 5901-5904, November 1979 Medical Sciences Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas (glibenclamide) SUAD EFENDIt*, FRANZ ENZMANNf, ANITA NYLtN*, KERSTIN UVNAS-WALLENSTENt, AND ROLF LUFT* *Department of Endocrinology, Karolinska Hospital, 104 01 Stockholm; tDepartment of Pharmacology, Karolinska Institute, 104 01 Stockholm, Sweden; and tHoechst Aktiengesellschaft, Medizinische Abteilung, Frankfurt, West Germany Contributed by Rolf Luft, July 27, 1979 ABSTRACT The effect of a sulfonylurea, glibenclamide, method and separated on CM-cellulose column. The antibodies on the release of insulin, glucagon, and somatostatin was studied produced in our laboratory were used at a final dilution of 1: in the isolated perfused rat pancreas. At concentrations glucose 56,000. Crossreactivity of the antibody was less than 0.01% with of 1.1 mM or less, the drug stimulated somatostatin release, whereas glucagon release, after 2-3 min of increase, was insulin, glucagon, substance P, luliberin, vasopressin, and ox- markedly inhibited. Insulin release was moderately stimulated, ytocin. The antigenic specificity of the antibodies was deter- and maximal release occurred relatively late. A moderate glu- mined by using somatostatin analogues (11). Phosphate buffer cose load (6.7 mM) inhibited glibenclamide-induced release of (0.04 M, pH 7.4) containing 1% bovine serum albumin was used somatostatin, whereas the two in combination exerted an ad- as the diluent for all components in this radioimmunoassay. ditive action on insulin release. Greater glucose loads, which by themselves would stimulate somatostatin release, only Incubations were for 48 hr at 4°C.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba
    Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba by Kim¡ T. G. Guilbert A Thesis submitted to The Faculty of Graduate Studies in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE Faculty of Pharmacy The University of Manitoba Winnipeg, Manitoba @ Kimi T.G. Guilbert, March 2005 TIIE UMYERSITY OF MANITOBA F'ACULTY OF GRADUATE STTJDIES +g+ù+ COPYRIGIIT PERMISSION PAGE Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba BY Kimi T.G. Guilbert A ThesisÆracticum submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfillment of the requirements of the degree of MASTER OF SCIENCE KIMI T.G. GTIILBERT O2()O5 Permission has been granted to the Library of The University of Manitoba to lend or sell copies of this thesis/practicum, to the National Library of Canada to microfïlm this thesis and to lend or sell copies of the film, and to University Microfilm Inc. to publish an abstract of this thesis/practicum. The author reserves other publication rights, and neither this thesis/practicum nor extensive extracts from it may be printed or otherwise reproduced without the author's written permission. Acknowledgements Upon initiation of this project I had a clear objective in mind--to learn more. As with many endeavors in life that are worthwhile, the path I have followed has brought me many places I did not anticipate at the beginning of my journey. ln reaching the end, it is without a doubt that I did learn more, and the knowledge I have been able to take with me includes a wider spectrum than the topic of population health and medication utilization.
    [Show full text]
  • Treatment Patterns, Persistence and Adherence Rates in Patients with Type 2 Diabetes Mellitus in Japan: a Claims- Based Cohort Study
    Open access Research BMJ Open: first published as 10.1136/bmjopen-2018-025806 on 1 March 2019. Downloaded from Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims- based cohort study Rimei Nishimura,1 Haruka Kato,2 Koichi Kisanuki,2 Akinori Oh,2 Shinzo Hiroi,2 Yoshie Onishi,3 Florent Guelfucci,4 Yukio Shimasaki2 To cite: Nishimura R, Kato H, ABSTRACT Strengths and limitations of this study Kisanuki K, et al. Treatment Objective To determine real-world trends in antidiabetic patterns, persistence and drug use, and persistence and adherence, in Japanese ► This retrospective evaluation of administrative adherence rates in patients patients with type 2 diabetes mellitus (T2DM). with type 2 diabetes mellitus claims data (2011–2015) using the Japan Medical Design Retrospective evaluation of administrative claims in Japan: a claims-based Data Center (JMDC) and Medical Data Vision (MDV) data (2011–2015) using the Japan Medical Data Center cohort study. BMJ Open databases was conducted to determine real-world (JMDC) and Medical Data Vision (MDV) databases. 2019;9:e025806. doi:10.1136/ trends in antidiabetic drug use, and persistence and Setting Analysis of two administrative claims databases bmjopen-2018-025806 adherence, in Japanese patients with type 2 dia- for Japanese patients with T2DM. betes mellitus (T2DM); 40 908 and 90 421 patients ► Prepublication history and Participants Adults (aged ≥18 years) with an International additional material for this were included from the JMDC and MDV databases, Classification of Diseases, 10th Revision code of T2DM and paper are available online. To respectively. at least one antidiabetic drug prescription.
    [Show full text]
  • A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D
    Drugs 2005; 65 (3): 325-340 REVIEW ARTICLE 0012-6667/05/0003-0325/$39.95/0 2005 Adis Data Information BV. All rights reserved. A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D. Mooradian Division of Endocrinology, Department of Internal Medicine, Diabetes, and Metabolism, St Louis University School of Medicine, St Louis, Missouri, USA Contents Abstract ....................................................................................325 1. Physiology of Insulin Secretion .............................................................326 2. Conventional Insulin Preparations ..........................................................327 3. Insulin Analogues ........................................................................328 3.1 Rapid-Acting Insulin Analogues .......................................................328 3.1.1 Insulin Lispro ...................................................................328 3.1.2 Insulin Aspart ..................................................................329 3.1.3 Insulin Glulisine .................................................................329 3.1.4 Clinical Utility of Rapid-Acting Insulin Analogues ...................................330 3.2 Premixed Insulins and Insulin Analogues ................................................331 3.3 Basal Insulin Analogues ...............................................................331 3.3.1 Insulin Glargine ................................................................331
    [Show full text]
  • (Pram) and Insulin A21G Improves Post-Prandial Glucose Vs Novolog
    ADO09, A Co-Formulation Of Pramlintide (Pram) and Insulin A21G improves Post-Prandial Glucose Vs Novolog® in Type 1 Diabetes (T1DM) G.Meiffren¹, G.Andersen², R.Eloy¹, C.Seroussi¹, C.Mégret¹, S.Famulla², Y.-P Chan¹, M.Gaudier¹, O.Soula¹, J.H. DeVries²,T.Heise² (1 Adocia, Lyon, France ; 2 Profil, Neuss, Germany) Introduction & Background Overall safety Outpatient period results - CGM metrics o ADO09 (M1Pram) is a co-formulation of pramlintide and insulin A21G o Both treatments were well tolerated without any treatment-related serious adverse events o Most of the CGM metrics (TiR [70-180], TiR [80-140], mean blood glucose per day), were significantly improved developed to leverage the beneficial effects of pramlintide on post-prandial (Table 2). As expected M1Pram had numerically more, mostly gastrointestinal adverse events with M1Pram (Table 4). Postprandial and mean 24-hour glucose profiles were improved with M1Pram (Fig. 3) glucose without additional injections than insulin aspart Table 4: CGM metrics, all days. Significant differences are marked in bold Objective and design o No severe hypoglycemia were seen, slightly more hypoglycemic events occurred with M1Pram Ratio of LSMean* o To compare the effect of M1Pram and insulin aspart (Novolog®, Novo than with aspart (Table 3) Difference Parameter Treatment LS Mean M1Pram / Aspart P-value Nordisk) on post-prandial glucose control, glycemic control assessed by Table 2: Incidence of adverse events throughout the trial (M1Pram-Aspart) (95% CI) CGM and safety/tolerability M1Pram Aspart M1Pram
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • Journal of Diabetes and Obesity
    Journal of Diabetes and Obesity Research Article Open Access The Different Association between Metformin and Sulfony- lurea Derivatives and the Risk of Cancer May be Confounded by Body Mass Index Catherine E. de Keyser1,2, Loes E. Visser1, Albert Hofman1, Bruno H. Stricker1,2*, Rikje Ruiter1# 1 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 2 The Health Care Inspectorate, The Hague, the Netherlands *Corresponding author: Bruno H. Stricker, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Netherlands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] #Submitting author: Rikje Ruiter, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Nether- lands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] Abstract Received date: July 09, 2016 Aim: Several studies in large databases suggest that in comparison to glucose-low- Accepted date: : September 05, 2016 ering sulfonylurea derivatives, metformin is associated with a reduced risk of cancer Publication date: September 12, 2016 in patients with diabetes. As many databases miss relevant confounder data, our objective was to investigate whether the determinants age, body mass index (BMI), alcohol consumption, and renal function were associated with dispensing of either Citation: Stricker, B.H., et al. The Dif- metformin or sulfonylurea derivatives as first drug therapy for type 2 diabetes mel- ferent Association between Metformin and litus while taking into account calendar time. Sulfonylurea Derivatives and the Risk of Methods: We identified 639 incident metformin users and 934 incident sulfonylurea Cancer May be Confounded by Body Mass derivatives users in the Rotterdam Study, a prospective population-based cohort Index.
    [Show full text]
  • Effects of Exenatide on Cardiac Function, Perfusion, and Energetics
    Chen et al. Cardiovasc Diabetol (2017) 16:67 DOI 10.1186/s12933-017-0549-z Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine Weena J. Y. Chen1*, Michaela Diamant1^, Karin de Boer2, Hendrik J. Harms3, Lourens F. H. J. Robbers2, Albert C. van Rossum2, Mark H. H. Kramer1, Adriaan A. Lammertsma3 and Paul Knaapen2 Abstract Background: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study was to investigate myocardial perfusion and oxidative metabolism in type 2 diabetic (T2DM) patients with LV systolic dysfunction as compared to healthy controls. Furthermore, efects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored. Methods and results: Twenty-six T2DM patients with LV systolic dysfunction (cardiac magnetic resonance (CMR) derived LV ejection fraction (LVEF) of 47 13%) and 10 controls (LVEF of 59 4%, P < 0.01 as compared to patients) were analyzed. Both myocardial perfusion± during adenosine-induced hyperemia± (P < 0.01), and coronary fow reserve 15 (P < 0.01), measured by ­[ O]H2O positron emission tomography (PET), were impaired in T2DM patients as compared to healthy controls. Myocardial oxygen consumption and myocardial efciency, measured using ­[11C]acetate PET and CMR derived stroke volume, were not diferent between the groups.
    [Show full text]